- Home
- CVAC vs AVXL Comparison
CVAC vs AVXL Comparison
Compare CVAC & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- AVXL
- Stock Information
- Founded
- CVAC 2000
- AVXL 2004
- Country
- CVAC Germany
- AVXL United States
- Employees
- CVAC N/A
- AVXL N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVAC Health Care
- AVXL Health Care
- Exchange
- CVAC Nasdaq
- AVXL Nasdaq
- Market Cap
- CVAC 764.4M
- AVXL 794.0M
- IPO Year
- CVAC 2020
- AVXL N/A
- Fundamental
- Price
- CVAC $5.39
- AVXL $10.60
- Analyst Decision
- CVAC Hold
- AVXL Strong Buy
- Analyst Count
- CVAC 3
- AVXL 2
- Target Price
- CVAC $6.83
- AVXL $44.00
- AVG Volume (30 Days)
- CVAC 2.2M
- AVXL 942.8K
- Earning Date
- CVAC 08-14-2025
- AVXL 08-05-2025
- Dividend Yield
- CVAC N/A
- AVXL N/A
- EPS Growth
- CVAC N/A
- AVXL N/A
- EPS
- CVAC 0.87
- AVXL N/A
- Revenue
- CVAC $566,039,775.00
- AVXL N/A
- Revenue This Year
- CVAC N/A
- AVXL N/A
- Revenue Next Year
- CVAC $24.04
- AVXL N/A
- P/E Ratio
- CVAC $6.29
- AVXL N/A
- Revenue Growth
- CVAC 787.60
- AVXL N/A
- 52 Week Low
- CVAC $2.37
- AVXL $4.00
- 52 Week High
- CVAC $5.72
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- CVAC 65.91
- AVXL 75.85
- Support Level
- CVAC $5.33
- AVXL $9.08
- Resistance Level
- CVAC $5.58
- AVXL $9.78
- Average True Range (ATR)
- CVAC 0.10
- AVXL 0.53
- MACD
- CVAC -0.04
- AVXL 0.19
- Stochastic Oscillator
- CVAC 41.67
- AVXL 95.03
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.